Brief: Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease
19/10/2021 01:54
Oct 19 (Reuters) - Living Cell Technologies Ltd LCT.AX :
* SECURED FUNDING FOR A THIRD CLINICAL TRIAL OF NTCELL IN
PARKINSON'S DISEASE
* COMPLETED PLACEMENT RAISING A$3.5 MILLION
Source text for Eikon: ID:nASXbgXbmM
Further company coverage: LCT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Algorae Pharmaceuticals
See all newsBrief: Algorae Pharmaceuticals Executes License & Supply Agreement With Torrent Pharma
Brief: Algorae Pharmaceuticals And Zydus Enter Exclusive Commercial Agreement
Brief: Algorae Pharmaceuticals Raises A$3.9 Million At A$0.012 Per Share
Brief: Algorae Pharmaceuticals Says TGA Accepts Initial Registration Dossier For Evaluation
Brief: Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre For Second AI-Driven Drug Synergy Screening Program